BOSTON--(BUSINESS WIRE)--Renovia Inc. (“Renovia”), a company dedicated to discovering and delivering first-line digital therapeutic and diagnostic devices for women with pelvic floor disorders, today announced that it has received a nomination for MedTech Company of the Year in the 2019 NEVY Awards hosted by the New England Venture Capital Association (“NEVCA”). The NEVYs, now in their seventh year, celebrate New England’s top innovators, investors and companies across the region’s health care, life science and tech communities.
“We are honored to be nominated by the New England Venture Capital Association for NEVYs MedTech Company of the Year award,” said Marc Beer, Co-Founder, Chairman and Chief Executive Officer of Renovia. “Pelvic floor disorders, including urinary incontinence, affect millions of women worldwide, have significant quality of life implications and can lead to severe medical conditions. However, despite its prevalence and adverse effects on women’s health, urinary incontinence is often underreported by women and thus not addressed by clinicians. By combining our innovative and proprietary sensor technologies with a digital health platform, Renovia can improve patient care and ultimately, we believe, lower long-term healthcare costs.”
Beer continued, “This NEVYs nomination acknowledges the hard work done by everyone at Renovia since our founding less than three years ago. I couldn’t be prouder of my Renovia colleagues and consider myself lucky to be leading such a talented and patient-focused team. On behalf of everyone at Renovia, I’d like to extend our deep appreciation to the New England Venture Capital Association and the NEVY team for this distinguished recognition.”
All NEVY Award nominees are based in New England and are selected by the NEVYs Academy, which is comprised of investors from New England’s top venture capital firms. Final NEVY Award winners will be named at The NEVYs Award ceremony on Wednesday, May 8 at Boston’s House of Blues. The 2019 NEVY Awards are sponsored by Dell Technologies, as well as IDA Ireland, Matter, Deloitte, Cooley LLP, Piper Jaffray, J&J Innovation, Inc. – JJDC, AbbVie Ventures, and Cowen.
Renovia was formed to develop and commercialize products for better first-line diagnosis and treatment to improve the condition-specific quality of life for millions of women with pelvic floor disorders. Renovia's technology enables treatment via precise visualization of pelvic movement in real-time during pelvic floor muscle training, while monitoring usage and progress over time. As a women's health organization, Renovia is in pursuit of scalable and cost-effective care for pelvic floor disorders delivered through the power of digital health. In 2018, Renovia launched its REDUCE study - a multi-center randomized controlled trial to compare Renovia’s next-generation leva® Pelvic Digital Therapeutic against standard of care pelvic floor muscle exercises in home-based treatment of stress-dominant urinary incontinence. For more information about Renovia, please visit here.